Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Lysogene raises €16.5mm via Series A led by Sofinnova

Executive Summary

Lysogene SAS (genetic neurodegenerative diseases) raised €16.5mm ($22.6mm) in a Series A financing led by seed backer Sofinnova Partners. First-time shareholders Bpifrance-affiliated Innobio and Novo Seeds co-led. Each investor contributed a board member.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies